73 related articles for article (PubMed ID: 24229757)
1. Phenoconversion of cytochrome P450 2D6: the need for identifying the intermediate metabolizer genotype.
Berm EJ; Risselada AJ; Mulder H; Hak E; Wilffert B
J Clin Psychiatry; 2013 Oct; 74(10):1025. PubMed ID: 24229757
[No Abstract] [Full Text] [Related]
2. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
3. Dr Preskorn replies.
Preskorn SH
J Clin Psychiatry; 2013 Oct; 74(10):1025-6. PubMed ID: 24229758
[No Abstract] [Full Text] [Related]
4. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
5. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
Preskorn SH
J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
[TBL] [Abstract][Full Text] [Related]
6. Alternative venlafaxine kinetics in overdose.
Langford NJ; Martin U; Ruprah M; Ferner RE
J Clin Pharm Ther; 2002 Dec; 27(6):465-7. PubMed ID: 12472987
[TBL] [Abstract][Full Text] [Related]
7. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
Zourková A; Hadasová E
Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2D6 genotype variation and venlafaxine dosage.
McAlpine DE; O'Kane DJ; Black JL; Mrazek DA
Mayo Clin Proc; 2007 Sep; 82(9):1065-8. PubMed ID: 17803873
[TBL] [Abstract][Full Text] [Related]
10. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and neurological toxicity of venlafaxine.
Blythe D; Hackett LP
Hum Exp Toxicol; 1999 May; 18(5):309-13. PubMed ID: 10372752
[TBL] [Abstract][Full Text] [Related]
12. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.
Ozdemir V; Tyndale RF; Reed K; Herrmann N; Sellers EM; Kalow W; Naranjo CA
J Clin Psychopharmacol; 1999 Oct; 19(5):472-5. PubMed ID: 10505591
[No Abstract] [Full Text] [Related]
13. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
[TBL] [Abstract][Full Text] [Related]
14. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2D6 poor metabolism, curvilinearity, and response: an intriguing observation requiring integration of psychopharmacology into pharmacogenetics.
Al Hadithy AF; Birkenhager TK; Koch BC
J Clin Psychopharmacol; 2013 Dec; 33(6):833-4. PubMed ID: 24196656
[No Abstract] [Full Text] [Related]
17. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen K; Neuvonen PJ; Laine K
Clin Pharmacol Ther; 2008 Feb; 83(2):342-8. PubMed ID: 17687273
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.
Ciusani E; Zullino DF; Eap CB; Brawand-Amey M; Brocard M; Baumann P
J Psychopharmacol; 2004 Dec; 18(4):559-66. PubMed ID: 15582923
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects.
Brockmöller J; Meineke I; Kirchheiner J
Clin Pharmacol Ther; 2007 May; 81(5):699-707. PubMed ID: 17329996
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine.
Nassan M; Nicholson WT; Elliott MA; Rohrer Vitek CR; Black JL; Frye MA
Mayo Clin Proc; 2016 Jul; 91(7):897-907. PubMed ID: 27289413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
